Compound: PROCAINAMIDE
SMILES: O=C(NCCN(CC)CC)c1ccc(N)cc1
InChIKey: REQCZEXYDRLIBE-UHFFFAOYSA-N
Synonyms: PROCAINAMIDE, 51-06-9, Novocainamide, Procaine amide, 4-Amino-N-[2-(diethylamino)ethyl]benzamide, Novocamid, Novocaine amide, Novocainamid, Biocoryl, Procamide, Procainamida, Procainamidum, p-Aminobenzoic diethylaminoethylamide, p-Amino-N-(2-diethylaminoethyl)benzamide, 4-Amino-N-(2-(diethylamino)ethyl)benzamide, Sp 100 (pharmaceutical), NSC-27461, Benzamide, 4-amino-N-(2-(diethylamino)ethyl)-, CHEBI:8428, L39WTC366D, DTXSID7023512, Benzamide, p-amino-N-(2-(diethylamino)ethyl)-, Benzamide, 4-amino-N-[2-(diethylamino)ethyl]-, DTXCID403512, Benzamide, p-amino-N-[2-(diethylamino)ethyl]-, Amide, Procaine, RefChem:55915, C01BA02, novocainamidum (for the hydrochloride), 200-078-8, 4-amino-N-(2-diethylaminoethyl)benzamide, Pronestyl, Procapan (free base), Procan, MFCD00066880, NSC 27461, Procainamide (INN), 2-Diethylaminoethylamid kyseliny p-aminobenzoove, NCGC00015859-07, PROCAINAMIDE [INN], Procanbid; SP 100; SP 100 (pharmaceutical), Procainamide [INN:BAN], Procainamidum [INN-Latin], Procainamida [INN-Spanish], Rhythmin, CAS-51-06-9, HSDB 3170, CAS-614-39-1, EINECS 200-078-8, (4-aminophenyl)-N-[2-(diethylamino)ethyl]carboxamide, BRN 2214285, UNII-L39WTC366D, 2-Diethylaminoethylamid kyseliny p-aminobenzoove [Czech], Spectrum_000836, 4-amino-N-(2-diethylaminoethyl) benzamide, Maybridge1_004389, Prestwick0_000337, Prestwick1_000337, Prestwick2_000337, Prestwick3_000337, Spectrum2_001295, Spectrum3_000555, Spectrum4_000487, Spectrum5_000986, Lopac-P-9391, CHEMBL640, Epitope ID:135397, PROCAINAMIDE [HSDB], Cambridge id 5144127, PROCAINAMIDE [VANDF], Lopac0_000995, SCHEMBL15914, BSPBio_000373, BSPBio_001463, BSPBio_002229, CBDivE_003757, KBioGR_000183, KBioGR_000973, KBioSS_000183, KBioSS_001316, 4-14-00-01154 (Beilstein Handbook Reference), cid_66068, BIDD:GT0579, DivK1c_000931, PROCAINAMIDE [WHO-DD], SPBio_001329, SPBio_002294, WLN: ZR DVM2N2&2, BPBio1_000411, GTPL4811, orb1689694, BDBM39344, HMS553P13, HY-A0084A, KBio1_000931, KBio2_000183, KBio2_001316, KBio2_002751, KBio2_003884, KBio2_005319, KBio2_006452, KBio3_000365, KBio3_000366, KBio3_001729, MSK9084, NINDS_000931, Bio1_000391, Bio1_000880, Bio1_001369, Bio2_000183, Bio2_000663, HMS1361J05, HMS1791J05, HMS1989J05, HMS2089E13, HMS3402J05, Tox21_110246, EBC-26266, SBB005866, STK367963, AKOS000271131, Tox21_110246_1, 4-Amino-N-(diethylaminoethyl)benzamide, CCG-205075, CS-W009100, DB01035, FS-5697, SDCCGSBI-0050968.P005, IDI1_000931, IDI1_033933, SMP1_000055, NCGC00015859-01, NCGC00015859-02, NCGC00015859-03, NCGC00015859-04, NCGC00015859-05, NCGC00015859-06, NCGC00015859-08, NCGC00015859-09, NCGC00015859-10, NCGC00015859-11, NCGC00015859-14, NCGC00015859-16, NCGC00015859-18, NCGC00015859-23, NCGC00024323-03, NCGC00024323-04, NCGC00024323-05, NCGC00024323-06, N-(2-Diethylaminoethyl) 4-aminobenzamide, ST077772, SY287819, SBI-0050968.P004, 4-amino-n-(2-diethylamino-ethyl)-benzamide, AB00053530, NS00001509, EN300-33971, N1-[2-(diethylamino)ethyl]-4-aminobenzamide, 4-{N-[2-(diethylamino)ethyl]carbamoyl}aniline, 4-Amino-N-[2-(diethylamino)ethyl]benzamide #, C07401, C75392, D08421, AB00053530-13, AB00053530-15, AB00053530_16, F237464, L001052, Q417597, N-(2-(DIETHYLAMINO)ETHYL)-4-AMINOBENZAMIDE, BRD-K75089421-001-02-5, BRD-K75089421-003-04-7, BRD-K75089421-003-05-4, BRD-K75089421-003-15-3, BRD-K75089421-003-24-5, F2173-1035, 4-azanyl-N-[2-(diethylamino)ethyl]benzamide;hydrochloride
Theoretical properties:
molecular_formula: C13H21N3O
molecular_weight: 235.33 g/mol
exact_mass: 235.168462302 g/mol
formal_charge: 0
hydrogen_bond_donor_count: 2
hydrogen_bond_acceptor_count: 3
rotatable_bond_count: 6
heavy_atom_count: 17
topological_polar_surface_area: 58.4 Å²
isotope_atom_count: 0
covalently_bonded_unit_count: 1
Physical properties:
melting_point: 165-169 °C
Descriptions:
pubchem: Procainamide is a benzamide that is 4-aminobenzamide substituted on the amide N by a 2-(diethylamino)ethyl group. It is a pharmaceutical antiarrhythmic agent used for the medical treatment of cardiac arrhythmias. It has a role as an anti-arrhythmia drug, a sodium channel blocker and a platelet aggregation inhibitor.
chebi: A benzamide that is 4-aminobenzamide substituted on the amide N by a 2-(diethylamino)ethyl group.  It is a pharmaceutical antiarrhythmic agent used for the medical treatment of cardiac arrhythmias.
chembl: PROCAINAMIDE is a small molecule listed in the ChEMBL database and has reached clinical trial phase 4.0.
wikipedia: Procainamide (PCA) is a medication of the antiarrhythmic class used for the treatment of cardiac arrhythmias. It is a sodium channel blocker of cardiomyocytes; thus it is classified by the Vaughan Williams classification system as class Ia. In addition to blocking the INa current, it inhibits the IKr rectifier K+ current. Procainamide is also known to induce a voltage-dependent open channel block on the batrachotoxin (BTX)-activated sodium channels in cardiomyocytes.